Acute Toxicity Study of Novel Melanoma Actives in Mice

Researcher Information

Abstract

Although there have been promising advances in melanoma drug discovery, the average overall survival of patients with late-stage metastatic melanoma is approximately 3 years, which suggests a need for identifying new melanoma targets. We previously reported a discovery of melanoma actives acting via binding and down regulating human nuclear ribonuclear protein H1/H2 (hnRNP H1/H2), which is a novel target with unknown toxicity. Therefore, the aim of this study was to study the safety of novel anti-melanoma compounds 2155-14 and 2155-18 in mice. The methodology of the study involved injecting male and female Balb/C mice three times a week for three weeks and monitoring them for signs of toxicity. At the end of the study, no signs of toxicity were found upon completion of blood and organ analysis, thereby suggesting that compounds 2155-14 and 2155-18 are safe to use for further in vivo studies.

Faculty Sponsors

Dr. Dmitriy Minond

Project Type

Event

Location

Alvin Sherman Library

Start Date

4-5-2023 12:00 PM

End Date

4-6-2023 4:00 PM

This document is currently not available here.

Share

COinS
 
Apr 5th, 12:00 PM Apr 6th, 4:00 PM

Acute Toxicity Study of Novel Melanoma Actives in Mice

Alvin Sherman Library

Although there have been promising advances in melanoma drug discovery, the average overall survival of patients with late-stage metastatic melanoma is approximately 3 years, which suggests a need for identifying new melanoma targets. We previously reported a discovery of melanoma actives acting via binding and down regulating human nuclear ribonuclear protein H1/H2 (hnRNP H1/H2), which is a novel target with unknown toxicity. Therefore, the aim of this study was to study the safety of novel anti-melanoma compounds 2155-14 and 2155-18 in mice. The methodology of the study involved injecting male and female Balb/C mice three times a week for three weeks and monitoring them for signs of toxicity. At the end of the study, no signs of toxicity were found upon completion of blood and organ analysis, thereby suggesting that compounds 2155-14 and 2155-18 are safe to use for further in vivo studies.